Low disease activity state in juvenile-onset systemic lupus erythematosus.

Ozturk K., Caglayan S., Tanatar A., Baglan E., Otar G. Y., Kayaalp G., ...Daha Fazla

Lupus, cilt.30, sa.13, ss.2144-2150, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 13
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1177/09612033211054399
  • Dergi Adı: Lupus
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2144-2150
  • Anahtar Kelimeler: Juvenile-onset systemic lupus erythematosus, low lupus disease activity state, LLDAS-50, DAMAGE, SLE, CLASSIFICATION, VALIDATION, REMISSION, SEVERITY, CRITERIA, THERAPY, COLLEGE
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objectives To determine the rate of achieving The Lupus Low Disease Activity State (LLDAS) in children with systemic lupus erythematosus (SLE) for tracing pertinent treatment modalities. Methods A total of 122 juvenile-onset SLE (jSLE) patients from six pediatric rheumatology centers in Turkey were enrolled in the study. LLDAS-50 was defined as encountering LLDAS for at least 50% of the observation time. According to the achievement of LLDAS-50, clinical features, immunological profiles, and treatments of patients with jSLE have been revealed. Results LLDAS of any duration was achieved by 82% of the cohort. Although only 10.8% of the patients achieved remission, 68.9% reached LLDAS-50. A significant difference was found between patients who reached LLDAS-50 and those who did not, in terms of the time to reach low-dose corticosteroid treatment (p = 0.002), the presence of subacute cutaneous findings (p = 0.007), and the presence of proteinuria (p = 0.002). Both of the groups were under similar treatment approaches. However, the number of patients being treated with corticosteroids at the last visit was found to be significantly higher in patients who achieved LLDAS-50 (p<0.001). Conclusion Targeting LLDAS in jSLE, even with long-term, low-dose corticosteroid use, seems to be an achievable goal in clinical practice.